Diet UltraSound Diabetes Cancer & Biopsy Germanium Heart Disease Free Radicals IV Chelation Therapy	Vibrant Life Home Web Family Of Three Chelation Formulas MSM Other VL Products The Wednesday Letter Frequently Asked Questions Testimonials	Karl Loren Web Shopping Cart	Separate Search Page or search below
Navigation Help	Oral Chelation Therapy Other	Ingredients Technical	Write To Karl Loren	Table Of Contents

Cancer chemo(toxico)therapy revisited and alternative ways of healing

Cancer & Biopsy

Cancer chemo(toxico)therapy revisited and alternative ways of healing.

A thesis presented to the Anglo-American Institute of Drugless Therapy and leading to the Degree of Doctor of Naturopathy (N.D.).

© 1990 by Dr.  Henri  Rosenberg.

 

TABLE OF CONTENTS

[Click on the Chapters' names  to reach them]
 
Introduction  2
Chapter I : Chemo(toxico)therapy 3
Chapter II : Amygdalin - Vitamin B 99
Chapter III : The Synthetic Physiatrons 128
Chapter IV : Trypanosoma Therapy 140
Chapter V : Selenium Therapy 146
Chapter VI : The beer's yeast cure 156
Chapter VII : Tumor related indicators 164
Chapter VIII : The Thymus Therapy 188
Chapter IX : The H-11 Therapy 194
Chapter X : Antineoplaston 202
Chapter XI : Gelum Oral RD® 205
Chapter XII : Neoblastine^® 212
Chapter XIII : The WIEDERMANN cure 219
Chapter XIV : Beetroot (juice) as cancer therapy 225
Chapter XV : Integral Fasting Therapy 229
Chapter XVI : The Iron Cancer Cure 235

Chapter XI

Gelum Oral RD^®

All biochemical processes and virtually all enzymatic reactions in a normal healthy body, can usually only take place at specific pH values of blood and tissue (+ 7.35 for blood) have only a very limited tolerance (7.27 - 7.45 in blood).
The pH value is the measured value of the hydrogen ion concentration in an isoelectric stress field, which is the result of the dissociation of acids, bases, and salt molecules (1).  The pH scale goes from 0 to 14, with 7 as the neutral point. pH's above 7 indicate alkalinity while those under 7 indicate acidity.
The natural buffer systems of the body ensure that the pH of blood and tissue remain within the normal (narrow) limits.   Many syndromes show at their onset certain shifts in the body's buffer systems.  After a time the buffering agent can no longer carry out its buffer function and the pH values will inevitably shift.
As I said at the beginning each enzymatic or biochemical process has its ideal pH.  Slight changes in the pH lead first to quantitative changes in enzyme activity but will at a later stage induce a qualitative change (2).  VON BREHMER (3), FREIHOFER (4), SEEGER (5), GOETZE (6), SZYLVAY (7), and others have shown, independently of one another, that in cancer patients there is nearly always (92 % of cases, according to FREIHOFER (8)) an upward shift in pH, or in other words towards increased alkalinity.
Normal oxygen supply to the cells is dependent on the physiological blood pH and a normal pO2 (oxygen pressure).  In such normal circumstances an optimum amount of CO2 will be transferred from the blood to the alveolae, so that an adequate quantity of O2 is absorbed and bonded to the haemoglobin.

When the cells give up their CO2 there is a local brief increase in H2CO3 concentration, causing the blood pH value to become slightly acidic and consequently furthering the giving up of O2 to the cell in accordance with the BOHR effect.
As has already been said, a shift in the blood buffer system will be preceded by an observable and quantifiable change in pH (using the "sanguinemeter" (9) of VON BREHMER).  This shift in the buffer system will in the long term give rise to a pathological pH and cause the cell oxidation to go over into glycolysis, causing cancer.  According to FREIHOFER, before any significant change in the blood pH becomes apparent a shortage of buffers such as phosphates and citrates will be apparent as a result of undernourishment (for example).  The body will react by attempting to produce a substitute buffer, by overproducing carbonic acid.  In the stage where the phospate-albumen-sodium buffer is disturbed by the excessive production of carbonic acid at the expense of the phosphate buffer, the pH of the blood will however not be altered.  The metamorphosis of the blood buffer does, however, favour alkalosis and a consequent oxygen shortage.  The BOHR effect referred to above will already be unfavourably influenced.  This oxygen shortage resulting from shifts in the buffer system and the consequent fixing of carbonic acid as a substitute buffer mechanism, is according to FINZ and WECK (10) - in keeping with the tradition of WARBURG and others, the cause of metabolic disorders (11)
The more the alkalinity of the blood departs from the physiological equilibrium, the greater will be the O2 shortage in the cell.  At a particular (critical) moment, an O2 danger threshold will be exceeded and the cell oxidation will go over into cell fermentation (12).

It is while this latent hypoxemia is gradually developing, before there is any change in pH (and a fortiori before any tumor has developed) that therapy can, and should, be used with the greatest chance of success (13).
A further consequence of the alkaline development of the blood pH is the increase in the viscosity of the blood.  This means that circulation speed falls and the passage of blood, particularly through the capillaries, is reduced.  Psychic factors (such as anxiety and stress) and the resulting spasms lead to the narrowing of the blood vessels (particularly the capillaries).  This reduces the volume of the circulated blood.
As a result of the fall in the volume and speed of the circulated blood, the transport speed of leucocytes and lymphocytes drops, with serious consequences for the body's defence mechanisms.
Contact between oxygen and cells is also slowed and metastases have more opportunities of colonizing particular areas.
Acting on the above arguments, an attempt has been made to formulate a potassium-iron-phosphate-citrate-buffer, sold under the name GELUM ORAL RD®, and then to study its effects on the formation and development of cancers, and metastasis first in laboratory animals and then clinically.
The experimental formulation of GELUM ORAL RD® contains, apart from potassium iron phosphate and potassium iron citrate, a dextrorotatory lactic acid (14), vitamin B complex, and a metabolic concentrate of substances which build up lactic acid.
1969 HOFMANN and SCHIEFER (15) of the Institute of Animal Pathology of Munich University investigated, under the guidance of Professor Dr SEDLMEIER, the buffer complex in rats with ascites hepatoma and Walker carcinosarcoma 256.
They could not observe any directly tumor destroying effects of GELUM ORAL RD®.  They ascribed their significant therapeutic successes with the experimental preparation to the non-specific stimulation of the lymphatic system.  Indeed they observed that in the group treated with GELUM ORAL RD® there was as an increase in lymphocytes in contrast with a fall in the number of lymphocytes in the control group, in other words the stimulation of the lymphatic system.

In 1960 HOEPKE and SCHEPELMANN (19) observed the stimulation of the spleen and thymus in cancerous rats which they had fed with an acid substance (by adding NH4Cl to their water) and concluded that they could reduce the pH (make it more acid) by means of their acidic food additives.
As according to FREIHOFER (16) and DAMMINGER (17) GELUM ORAL RD® affects the blood pH, HOFMANN and SHLIEFER suggested that their favourable results (stimulation of the spleen and thymus and consequently the lymphatic system) could well be the result of acidification by influencing the pH.
In 1969 BRAUN, GERICKE, KOVAC, and SPANGLER (18) investigated, using laboratory animals at first, whether GELUM ORAL RD® a) had any effect on the occurrence of cancer and metastasis and b) acted as a non-specific stimulant of the immune system.
With respect to the latter the animal experiments of 1960 (HOEPKE and SCHEPELMANN) and 1969 (HOFMANN and SCHIEFER), merely provided evidence of the stimulation of the spleen and thymus (RES) and of the lymphatic system (leucotyse) respectively, without providing evidence of greater specific immunity.  This was the object of these experiments.
As for a), the occurrence of cancer, these four Viennese cancer researchers show that fibrosarcoma development could be prevented by a treatment with GELUM ORAL RD® for 8 days prior to the inducement of tumor with 3 methylcholantrene and that when the experimental preparation was given after the tumor had been induced its development could at least be significantly slowed and delayed in comparison with the control group.
The action of GELUM ORAL RD® on the metastasis (as well as a)) was investigated with reference to Yoshida ascites hepatoma (AH 130 (16)) in rats.   This could not be slowed or delayed using the experimental preparation (20).

From the studies of HOEPKE and SCHEPELMANN (1960) and HOFMANN and SCHIEFER (1969) it could be expected (as working hypothesis) that the experimental preparation could, besides activating the RES and lymphatic system, further the stimulation of the immune system item b) above.
If GELUM ORAL RD® was capable of producing an immunostimulative effect, it should therefore be capable of preventing or at least moderating illness in the event of infection.  On the other hand the experimental preparation should also have a favourable effect on the humoral defence mechanism, which according to BIELING (21) and GERICKE (22) is expressed as a transitory increase of the antibody titer.
Male white mice were infected with salmonella typhi murium after half of the mice had been given a preliminary treatment with the experimental preparation.  There was no significant difference in the progression of the disease between the two groups.  The number of mice which died of peritonitis and sepsis in both groups was virtually the same.  In a second test the antibody titer of rabbits immunized against salmonella typhosa was measured.  Whether these rabbits had been handled with GELUM ORAL RD® made no difference to the results of the test.
Disease can therefore not be prevented after infection nor can its symptoms be alleviated.  Furthermore no anamestic reaction could be induced.
Encouraged by the ability of the experimental preparation to prevent tumor development upon tumor induction when administered in advance, or at least to slow development when administered after induction, as indicated by the fibrosarcoma induced in mice by 3-methylcholantrene described above, BRAUN et alia proceeded to carry out clinical tests with GELUM ORAL RD in the postoperative treatment of organic carcinoma of stomach and intestines.
The indicator of successful treatment used was the period of survival of the patients, as determined by internationally agreed standards.

The extension of survival times (apart from the undeniable subjective improvements) was found to be highly significant and in their conclusions the 4 researchers argue for the widespread therapeutic application of the experimental preparation in battle against cancer, even though there is no complete explanation of the operating mechanism.  Non-specific immunity must, however be ruled out.
 

Operation
 

Composition

(...)
 

Manufacturer

Dreluso Pharmazeutika
Dr. Elten & Sohn
Markt 5
Postfach 140
D-3253  Hess. Oldendorf
Federal Republic of Germany
phone : (05152) 2042
 

 __________________________________________________
 

Footnotes :

(1) The pH is approximately the negative logarithm of the H+ concentration expressed as a molarity.

(2) For example the enzyme will produce a different substance when the pH is not the same as that in physiological milieu.  Consider the production of acetone in diabetes.  In alkaline milieu acetic acid
 (2 x CH3COOH + C2H5OH) will be created from CH3COCH2COOC2H5, while in a neutral solution acetone (CH3COCH3 + CO2 + C2H5OH) will be created.  It is thus obvious that diabetes therapies will attempt to correct the blood buffer system in order restore ordinary enzyme function.

(3) VON BREHMER, Siphonsata polimorpha, Linck Verlag, Haag/Amper (1947)

(4) FREIHOFER O., Der Blut-pH-Wert und seine Bedeutung für das Krebsgeschehen,
 Der Kassenartz, Heft 4 (1974) pp 666 -669

(5) SEEGER P.G.,Der Einfluss vershiedener Substanzen auf die Atmungsintensitat  von Krebszellen und Normalblut der Maus, Hippokrates 30/59, no 22.

(6) GOETZE E.G., Lehrbuch der pathologischen Physiologie, VEB Gustav Fischer Verlag Jena (1964)
(7) SZYLVAY, Grundlageforschung uber Krebs und Leukemie.

(8) FREIHOFER O., o.c.

(9) In contrast to newer pH measuring instruments the sanguinemeter of VON BREHMER measures the pH of the circulating blood, which according to VON BREHMER and FREIHOFER is vital if a correct picture of the cancer process is to be formed.

(10) FINZ R. and WECK J. Die Storung des bio-physikalischen Gleichwichtes als Ursaches maligner Stoffwechselentgleisungen, Krebsgeschehen, Heft 4 (1975).

(11)  see Chapter .......page .......

(12)  see the chapter on lactic acid, page .......

(13) This hypoxemia is according to FREIHOFER not only the prime cause of tumors, but also of numerous other diseases.  Without, or with only a little, oxygen the liver cannot adequately carry out its detoxification function.  Besides caring for the energy metabolism, the liver attends to the detoxification of the intestine, removing the poisonous metabolic products of the paracoli, i.e. indole,  which accumulate in the intestine when blood pH is pathological.  If it cannot or can only partially carry out this second function, small traces of toxins will enter the bloodstream and cause the most diverse diseases.  By treating these diseases without taking the above into account, it is in FREIHOFER'S opinion ...........

(14)

(15)
 

 FREIHOFER O., Bericht an die Fa. Dreluso (1967)
(16) FREIHOFER O., De Blut-pH-Wert und seine Bedeutung für das Krebgeschehen, Der Kassenartz, Heft 4 (1974)

(17) DAMMINGER, Bericht an die Fa. Dreluso (1967)

(18) from the University Children's Clinic, Vienna; Institute for General and Experimental Pathology of the University of Vienna; Surgical Department of the Krankefursorgeanstalt der Bediensteten, Vienna; Laboratory for Cancer Research of the Hoechst-Farbwerke AG, Frankfurt am Main.
 BRAUN F., GERICKE D., KOVAC W., SPANGLER H.P., Adjuvante Therapie bei Karzinomen des Magen-Darm-Traktes with a Puffersystem (Gelum_), Tierexperimentelle und klinische Untersuchungen, Therapiewoche, 29 (1979)

(19) YOSHIDA T., Dtsch med Wschr. 88. pp 2229 (1963)

(20) In their conclusions, however, the 4 researchers observe that this finding does not exclude all influence of the experimental preparation on metastasis.  The research was after all carried out on an vigorously growing tumor (i.e. Yoshida-ascites hepatoma, see note (4) above) where the degree of metastasis depends on the number of implanted tumor cells.  (see YOSHIDA T. in Virchow's Arch. 330, page 85, 1957).  It is thus definitely possible - according to the conclusions of the 4 scientists - that the number of implanted cells was too great for GELUM ORAL RD® to have any effect.

(21) BIELING J. Behringwerke-Mitteilungen, 8 (1937)

(22) GERICKE D. Medizinische, 16 (1952)

(23)
 
 

Dr.  Henri  ROSENBERG, LL.D., Ph.D., N.D.
Doctor of Naturopathy
Permanent Member of the British
Guild of Drugless Practitioners.

 

SUBSCRIBE:  The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren.  You can view more than 50 back issues of this publication by clicking here.  The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter.  It is automatically published on the Tuesday night just before the first Wednesday of every month.  You can subscribe to this free monthly electronic letter by entering your eMail address and name below.  You will then automatically receive a request for confirmation, sent to whatever address you have entered.  If you do NOT receive this confirmation request, then you will not be subscribed.  There may have been an error with your address and you should resubmit.  The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription.  When you receive this confirmation request you must reply to it, or your subscription will not become active.  No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.

REMOVAL:  You can remove yourself from the subscription list in several different ways.  Click here to read about this entire newsletter system.  Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list.  If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed.  Thus, no one else can unsubscribe you, from some other computer, without your knowledge.  But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.

Personal Message:  When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions.  Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US.  You can select particular information you would like to receive, along with the free cassette tape and catalog.